Archive

Dr. Goldman’s human glial mouse model has been written up in New Scientist. The idea is not to mimic fiction, but to advance our understanding of human brain diseases by studying them in whole mouse brains rather than in dishes. The altered mice still have

Four prominent Rochester researchers shared the state of their research and their experiences discovering and developing useful drugs. Mark Noble, Ph.D., (Biomedical Genetics), Paul Dunman, Ph.D. (Microbiology & Immunology), Harold Smith, Ph.D. (Biochemistry & Biophysics), and Richard Phipps, Ph.D. (Environmental Medicine) all spoke about some

High Tech Rochester’s Lennox Tech Enterprise Center, by virtue of its association with the University of Rochester, is a tax-free zone under the new START-UP NY economic development program. Taking advantage of HTR’s designation, PharmAdva LLC (www.pharmadva.com), a startup healthcare technology company with roots at

The University of Rochester has been identified by the journal Nature Biotechnology as one of the top 10 universities in the nation for the impact of its life sciences research. “This recognition reflects not only the University’s success in attracting federal research funding, but our ability to

They started with 6,932 applications from 96 countries and all 50 states. On 30 October 2014, the 11 finalists pitched their business plans to the judges. And the results are . . . Click here

PharmAdva LLC, a medical device manufacturer, has been approved to participate in the START-UP NY economic development program. The company will locate in High Tech Rochester’s (HTR) Lennox Tech Enterprise Center in Henrietta. Read More  

By KERRY FELTNER Rochester Business Journal October 8, 2014 Adarza BioSystems Inc. has completed its final tranche of fundraising, reaching a total of $6.8 million. The funds will be used toward development of its immunoassay product and will accelerate development of even more sensitive tests for

The fall 2014 round of the Technology Development Fund (TDF) has started.  The TDF awards winning applications from faculty, staff, or students up to $100,000 to develop their technology to a commercial endpoint.  A submitted invention disclosure to UR Ventures is required for an application. 

As of Wednesday, 17 September 2014 UR Ventures has moved to a new location in the Saunders Research Building. We have kept our mailing address, all of our phone numbers, and e-mail addresses. The only difference is our physical location — SRB suite B360. The

Researchers at the University of Rochester Medical Center and University of Nebraska Medical Center have received a $3.4 million grant from the National Institutes of Health to study an experimental drug combination that appears to rid white blood cells of HIV and keep the infection

Rochester Business Journal 12 August 2014 The Entrepreneurs Network is soliciting applications for its 17th class, with sessions to begin next month. The class will meet monthly at High Tech Rochester Inc. in Henrietta and other venues in the Rochester area beginning Sept. 18 and

Experiment measures millions of quantum trajectories to predict ‘most likely’ route As a quantum state collapses from a quantum superposition to a classical state or a different superposition, it will follow a path known as a quantum trajectory. For each start and end state there

Recently, 113 semi-finalists were announced in the 2014 43 North $1 million business plan competition. Ten of those semi-finalists are from the Rochester area. Four of those are connected to University of Rochester technologies. Health Care Originals (Rochester, NY) is negotiating a license for a

Recently, 113 semi-finalists were announced in the 2014 43 North $1 million business plan competition. Ten of those semi-finalists are from the Rochester area. Four of those are connected to University of Rochester technologies. Ovitz Corporation (West Henrietta, NY) intends to develop and commercialize a

Recently, 113 semi-finalists were announced in the 2014 43 North $1 million business plan competition. Ten of those semi-finalists are from the Rochester area. Four of those are connected to University of Rochester technologies. Raland Therapeutics, Inc. (Fairport, NY) has licensed three technologies from the